You are here

Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant Recipients

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Renal Transplantation
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
13 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Age greater than or equal to 13 years.

- Receiving CsA or tacrolimus from the time of transplantation or within 2 weeks
thereafter

- Patients with a functioning allograft and a Nankivell GFR greater than or equal to 20
mL/min, within 2 weeks before randomization

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Biopsy-confirmed acute rejection within 12 weeks before randomization, that was
determined to require antirejection treatment

- Patients in whom kidney-pancreas or other multiple organ transplants have been
performed

NCT00038948
Pfizer
Completed
Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant Recipients

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now